Plasma gelsolin: In search of its raison d'être. Focus on "Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin"

American Journal of Physiology - Cell Physiology

Volumn 292, Issue 4, 2007, Pages

  DiNubile, Mark J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ANTIBIOTIC AGENT; GELSOLIN; LYSOPHOSPHATIDIC ACID; RECOMBINANT PROTEIN; THROMBOCYTE ACTIVATING FACTOR; VITAMIN D BINDING PROTEIN;

ACTIN FILAMENT; ASTHMA; CELL DAMAGE; CELL DISRUPTION; CELL MIGRATION; CELL MOTILITY; CHEMOTAXIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DEPOLARIZATION; DRUG POTENTIATION; EDITORIAL; EXTRACELLULAR SPACE; HUMAN; INFLAMMATORY CELL; INTERSTITIAL FLUID; INTRACELLULAR FLUID; NONHUMAN; ORGAN INJURY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEIN FUNCTION; SEPSIS;

ANIMALS; GELSOLIN; HUMANS; LYSOPHOSPHOLIPIDS; OLIGOPEPTIDES; PLATELET ACTIVATING FACTOR; RECOMBINANT PROTEINS; SUPEROXIDES; UP-REGULATION;

EID: 34247384538     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00007.2007     Document Type: Editorial

References (38)

1. Becker PM, Kazi AA, Wadgaonkar R, Pearse DB, Kwiatkowski D, Garcia JG. Pulmonary vascular permeability and ischemic injury in gelsolin-deficient mice. Am J Respir Cell Mol Biol 28: 478-484, 2003.
2. Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Chaby R, Janmey PA. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 44: 9590-9597, 2005.
3. Candiano G, Bruschi M, Pedemonte N, Caci E, Liberatori S, Bini L, Pellegrini C, Vigano M, O'Connor BJ, Lee TH, Galietta LJ, Zegarra-Moran O. Gelsolin secretion in interleukin-4-treated bronchial epithelia and in asthmatic airways. Am J Respir Crit Care Med 172: 1090-1096, 2005.
4. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 50: 54-60, 2002.
5. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Muzykantob VR, Machtay M, Albelda SM, DiNubile MJ. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung 180: 91-104, 2002.
6. Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Opal S, Laterre PF, Abraham D, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente J, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 32: 332-341, 2004.
7. Dahl B, Schiodt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock 12: 102-104, 1999.
8. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood 100: 4367-4371, 2002.
9. Erukhimov JA, Tang ZL, Johnson BA, Donahoe MP, Razzack JA, Gibson KF, Lee WM, Wasserloos KJ, Watkins SA, Pitt BR. Actincontaining sera from patients with adult respiratory distress syndrome are toxic to sheep pulmonary endothelial cells. Am J Respir Crit Care Med 162: 288-294, 2000.
10. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 275: 14573-14578, 2000.
11. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA 87: 381-385, 1990.
12. Heintzelman MB, Frankel SA, Artavanis-Tsakonas S, Mooseker MS. Cloning of a secretory gelsolin from Drosophila melanogaster. J Mol Biol 230: 709-716, 1993.
13. Ito H, Kanbe H, Kimura Y, Nakamura H, Hayash E, Kishimoto T, Kishimoto S, Yamamoto H. Depression of plasma gelsolin during acute liver injury. Gastroenterology 102: 1686-1692, 1992.
14. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. Muscle is the major source of plasma gelsolin. J Biol Chem 263: 8239-8243, 1988.
15. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 323: 455-458, 1986.
16. Lee PF, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma gelsolin levels in outcomes of critically ill surgical patients. Ann Surg 243: 399-403, 2006.
17. Lee PS, Waxman AB, Magnuson T, Chung SW, Cotich BA, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. In press.
18. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 326: 1335-1341, 1992.
19. Leifeld L, Fink K, Debska G, Fielenbach M, Schmitz V, Sauerbruch T, Spengler U. Anti-apoptotic function of gelsolin in fas antibody-induced liver failure in vivo. Am J Pathol 168: 778-785, 2006.
20. Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev Respir Dis 138: 429-434, 1988.
21. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 78: 736-742, 1986.
22. Maury CP, Rossi H. Demonstration of a circulating 65K gelsolin variant specific for familial amyloidosis, Finnish type. Bio Chem Bio Phys Ref Commun 191: 41-44, 1993.
23. Mounzer KC, Moncure M, Smith YR, DiNubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 160: 1673-1681, 1999.
24. Ohsawa M, Kimura H. Formation of vitamin D-binding protein-actin and binary and ternary plasma gelsolin-actin complexes in human serum. Biochim Biophys Acta 992: 195-200, 1989.
25. Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol 292: C1323-C1330, 2007.
26. Park SM, Hwang IK, Kim SY, Lee SJ, Park KF, Lee FT. Characterization of plasma gelsolin as a substrate as a matrix for metalloproteinases. Proteonics 6: 1192-1199, 2006.
27. Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 96: 25-31, 2004.
28. Russell MA. Management of sepsis. N Engl J Med 355: 1699-1713, 2006.
29. Smith DB, Janmey PA, Lind SE. Circulating actin-gelsolin complexes following oleic acid-induced lung injury. Am J Pathol 130: 261-267, 1988.
30. Smith DB, Janmey PA, Sherwood JA, Howard RJ, Lind SE. Decreased plasma gelsolin levels in patients with Plasmodium falciparum malaria: a consequence of hemolysis. Blood 72: 214-218, 1988.
31. Suhler E, Lin W, Yin HL, Lee WN. Decreased plasma gelsolin concentration in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 25: 594-598, 1997.
32. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263: 969-971, 1994.
33. Vasconcellos CA, Lind FE. Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein. Blood 82: 3648-3657, 1993.
34. Weeds AG, Grooth J, McLaughlin P, Maury CP. Variant plasma gelsolin responsible for familial amyloidosis (Finnish type) has defective actin severing capacity. FEBS Lett 335: 119-123, 1993.
35. Wen D, Corina K, Chow EP, Miller S, Janmey PA, Pepinsky RB. The plasma and cytoplasmic forms of human gelsolin differ in disulfide structure. Biochemistry 35: 9700-9709, 1996.
36. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 28: 738-745, 2003.
37. Witke W, Sharpe H, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 1: 41-51, 1995.
38. Zimmerman GA, McIntyre TM, Prescott SM, Stafforini DM. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30: S294-S301, 2002.